ArticleAmerican journal of translational research2025
Delayed uveitis after implantable Collamer lens Implantation caused by COVID-19 infection: a case report.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report presents a case of uveitis secondary to ankylosing spondylitis (AS) with abnormal exudative deposits and pigment adhesion on the surface of an implantable Collamer lens (ICL) in a highly myopic eye following coronavirus disease 2019 (COVID-19) infection. The etiology and treatment were analyzed. A 22-year-old male presented with decreased visual acuity in the right eye, having undergone bilateral ICL implantation for high myopia 22 months prior. During the COVID-19 pandemic, he developed ocular exudation, pigment deposition, and vision deterioration, with a confirmed diagnosis of AS. Therapeutic interventions included anti-inflammatory, antiviral, and corticosteroid therapies. Postoperative uveitis secondary to AS following ICL implantation represents a rare complication. COVID-19 infection and concurrent systemic autoimmune disorders were identified as risk factors for secondary iridocyclitis. Immunological testing confirmed AS diagnosis. Treatment with sodium hyaluronate eye drops, ganciclovir ophthalmic gel, and systemic corticosteroids improved symptoms; however, persistent punctate exudates and pigment deposits on the ICL surface exhibited limited resolution. For patients with systemic autoimmune diseases or virus-induced uveitis undergoing ICL implantation, preoperative immunological screening should be actively performed to minimize postoperative complications. Early comprehensive therapy is critical to prevent progressive vision loss and rare transparency alterations of the ICL surface caused by pigment-laden exudates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.